SDM laser effective for CSC

Article

According to recently published data, an 810 nm subthreshold diode micropulse (SDM) laser is effective in the treatment of chronic central serous chorioretinopathy (CSC).

According to recently published data, an 810 nm subthreshold diode micropulse (SDM) laser is effective in the treatment of chronic central serous chorioretinopathy (CSC).

The study, performed by Dr Luiz Roisman et al. (Federal University of Sao Paulo, Brazil), included 15 patients in total who were randomized into two groups to either receive SDM laser treatment or a sham procedure.

Ten patients received SDM laser treatment along the detached area, the remaining five patients received sham treatment. At 3 months follow up, the best-corrected visual acuity (BCVA) was found to be significantly improved in the laser treatment group. All patients allocated to the sham group required treatment after 3 months. Central macular thickness was noted to be better in both groups.

It was concluded that SDM laser treatment was effective in the treatment of chronic CSC without causing any damage to the retina.

For more detailed information please view the abstract in Ophthalmic Surgery, Lasers and Imaging.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.